Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00518466 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults

A Phase 1 study, sponsored by VIVUS.

Completed
Registry status
Phase 1
Development phase
64
Enrollment target

NCT00518466 is a Phase 1 study that has completed, run by VIVUS. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00518466, a Phase 1 study, has completed, sponsored by VIVUS.

COMPLETED
Registry status
Phase 1
Development phase
64 participants
Enrollment target

Study Summary

The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

Interventions

  • DRUG topiramate
  • DRUG phentermine

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2007-07
Est. Completion 2007-12
Phase Phase 1

Sponsor

VIVUS

35 total trials

What the Registry Record Tells You About NCT00518466

The ClinicalTrials.gov registry entry for NCT00518466 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VIVUS, which has 35 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which topiramate is the first listed.

NCT00518466 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00518466 about?

NCT00518466 is a clinical study titled "Pharmacokinetic Comparison of Multiple Formulations of Topiramate and Phentermine in Obese Adults". The primary objective of this study is to describe the single- and multiple-dose pharmacokinetic profiles of two novel formulations of topiramate and commercially available immediate release topiramate, all dosed with immediate release phentermine.

What is the current status of trial NCT00518466?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2007-07. Estimated completion is 2007-12.

What interventions are being tested in trial NCT00518466?

The interventions under investigation include: topiramate (DRUG), phentermine (DRUG).

Who is sponsoring clinical trial NCT00518466?

This trial is sponsored by VIVUS, which has 35 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.